Cybin Inc., a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, announced on December 1, 2021 that the U.S. Food and Drug Administration (“FDA”) has authorized a Phase 2 clinical trial evaluating psychedelic-assisted psychotherapy with psilocybin for healthcare workers experiencing COVID-related distress. The trial will be conducted at the University of Washington and will aim to treat symptoms of depression, anxiety, burnout and post-traumatic stress among frontline doctors, nurses and other healthcare professionals.
“This study offers an important opportunity to assess psychedelics-assisted therapy as a new modality for clinicians who have suffered as a result of their frontline work in the pandemic”Dr. Anthony Back
This trial will be hosted in Seattle, a city significantly impacted by the COVID-19 pandemic and will be funded by multiple organizations. “This study offers an important opportunity to assess psychedelics-assisted therapy as a new modality for clinicians who have suffered as a result of their frontline work in the pandemic,” said Dr. Anthony Back.
The Phase 2 clinical trial will enroll 30 frontline clinicians. Inclusion criteria include clinically significant symptoms of depression and anxiety and existential distress following work exposure during the COVID pandemic. The trial will employ a randomized parallel design methodology using an active placebo.
This new trial not only tackles an important condition — looking at Covid-related distress specifically and trauma more generally — but it also adds to the company’s growing pipeline of developmental programs. Good news for both investors and future patients.
Read the full release here and stay tuned for more news on this trial!